• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line).
  

PubMed=7060019
Parsons P.G., Smellie S.G., Morrison L.E., Hayward I.P.
Properties of human melanoma cells resistant to 5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other methylating agents.
Cancer Res. 42:1454-1461(1982)

PubMed=6534346; DOI=10.1038/icb.1984.57
Hayward I.P., Parsons P.G.
Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells.
Aust. J. Exp. Biol. Med. Sci. 62:597-606(1984)

PubMed=6690060
Hayward I.P., Parsons P.G.
Comparison of virus reactivation, DNA base damage, and cell cycle effects in autologous human melanoma cells resistant to methylating agents.
Cancer Res. 44:55-58(1984)

PubMed=3756862
Maynard K., Parsons P.G.
Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.
Cancer Res. 46:5009-5013(1986)

PubMed=3127479; DOI=10.1111/1523-1747.ep12461022
McEwan M., Parsons P.G., Moss D.J.
Monoclonal antibody against human tyrosinase and reactive with melanotic and amelanotic melanoma cells.
J. Invest. Dermatol. 90:515-519(1988)